Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;8(1):4-11.
doi: 10.1177/2040622316672544. Epub 2016 Nov 24.

Ezetimibe: an update on its clinical usefulness in specific patient groups

Daniel Hammersley  1 , Mark Signy  2
Affiliations
Review

Ezetimibe: an update on its clinical usefulness in specific patient groups

Daniel Hammersley et al. Ther Adv Chronic Dis. 2017 Jan.

Abstract

The aim of pharmacological lipid modification is to reduce low-density lipoprotein cholesterol (LDL-C) as a means of either secondary or primary prevention of cardiovascular disease. Statins are the first-line therapy for pharmacological lipid modification. Ezetimibe is a drug which reduces LDL-C by selectively inhibiting intestinal cholesterol absorption. This provides an alternative pharmacological approach to that of statin therapy to reduce LDL-C. Ezetimibe has been shown to significantly reduce levels of LDL-C and recently, as demonstrated in the IMPROVE-IT trial, to reduce the rate of cardiovascular events in high-risk patients. Ezetimibe therefore has an important role in pharmacological lipid modification. In this paper, we examine the body of research behind ezetimibe and assess its current clinical applications in different patient subgroups.

Keywords: cholesterol; dyslipidaemias; ezetimibe; hypercholesterolaemias; hyperlipidaemia; lipids; low-density lipoprotein.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Dr Signy is an IMPROVE-IT investigator, has been a paid speaker and a member of paid advisory boards for MSD.

References

    1. Baigent C. (2015) Cholesterol metabolism and statin effectiveness in hemodialysis patients. J Am Coll Cardiol 65: 2299–2301. - PubMed
    1. Baigent C., Landray M., Reith C., Emberson J., Wheeler D., Tomson C., et al. (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377: 2181–2192. - PMC - PubMed
    1. Ballantyne C., Houri J., Notarbartolo A., Melani L., Lipka L., Suresh R., et al. (2003) Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107: 2409–2415. - PubMed
    1. Banach M., Nikolic D., Rizzo M., Toth P. (2016) IMPROVE-IT: what have we learned? Curr Opin Cardiol 31: 426–433. - PubMed
    1. Banach M., Rizzo M., Toth P., Farnier M., Davidson M., Al-Rasadi K., et al. (2015) Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel. Arch Med Sci 11: 1–23. - PMC - PubMed

LinkOut - more resources